What is the importance of using an IMiD/PI triplet in relapsed/refractory myeloma?

Dr Charlotte Pawlyn, Professor Gordon Cook and Dr Rakesh Popat discuss the importance of using an immunomodulatory drug/proteasome inhibitor triplet in relapsed/refractory multiple myeloma.

The views expressed in this video are those of the speakers.

UK/NP/1806/0035n - August 2018

You are now leaving the Myeloma Hub

This link opens another website that is not under the review or control of Takeda UK Ltd and, as such, the company does not endorse the content, its accuracy, or any practices or standards contained within it. Please confirm you wish to continue.